Replies to post #125894 on Biotech Values

[mcbio]

So if DM-1 gets approved end of 2012, then you are talking a couple of years of royalties only. And for Bapineuzumab the situation is even worse.

Yes, I didn't realize that those patents are essentially relevant for all of PDLI's pipeline.